Niagen Bioscience Inc (NAGE)
Automate Your Wheel Strategy on NAGE
With Tiblio's Option Bot, you can configure your own wheel strategy including NAGE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NAGE
- Rev/Share 1.387
- Book/Share 0.5924
- PB 19.8855
- Debt/Equity 0.0575
- CurrentRatio 3.5715
- ROIC 0.2494
- MktCap 927907066.0
- FreeCF/Share 0.1535
- PFCF 77.6751
- PE 64.9842
- Debt/Assets 0.0388
- DivYield 0
- ROE 0.4026
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | NAGE | Canaccord Genuity | -- | Buy | -- | $13 | May 27, 2025 |
News
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Niagen Bioscience (NAGE) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.01 per share a year ago.
Read More
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
Published: April 28, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Bioscience--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours o.
Read More
Niagen Bioscience Secures U.S. Patent for the Composition of Matter for Nicotinamide Riboside (NR) Salt Forms
Published: March 20, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #IP--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent 12,252,506, which covers the composition of matter for nicotinamide riboside (NR) salt forms, including NR Malate and NR Tartrate, and other NR derivatives. This is p.
Read More
About Niagen Bioscience Inc (NAGE)
- IPO Date 2015-06-24
- Website https://www.niagenbioscience.com/
- Industry Biotechnology
- CEO Mr. Robert N. Fried
- Employees 104